Stage II to III (T1CN1-2 or T2-4N0-2) TNBC breast cancer

Clinical trials for Stage II to III (T1CN1-2 or T2-4N0-2) TNBC breast cancer explained in plain language.

Never miss a new study

Get alerted when new Stage II to III (T1CN1-2 or T2-4N0-2) TNBC breast cancer trials appear

Sign up with your email to follow new studies for Stage II to III (T1CN1-2 or T2-4N0-2) TNBC breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New drug duo aims to shrink aggressive breast cancer before surgery

Disease control Not yet recruiting

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and pembrolizumab—given before surgery to people with stage II or III triple-negative breast cancer. The goal is to see if the treatment can completely eliminate the cancer by the time of surgery. The stu…

Matched conditions: STAGE II TO III (T1CN1-2 OR T2-4N0-2) TNBC BREAST CANCER

Phase 2 • Sponsor: Yantai Yuhuangding Hospital • Aim: Disease control

Last updated Jun 27, 2026 07:52 UTC

Stage II to III (T1CN1-2 or T2-4N0-2) TNBC breast cancer

Get alerted when new Stage II to III (T1CN1-2 or T2-4N0-2) TNBC breast cancer trials appear

New drug duo aims to shrink aggressive breast cancer before surgery